Showing 301-310 of 328 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Targeted delivery of therapeutics to islet beta cells for preventing and treating diabetes | UT Southwestern | Juanzhu Yan | Cures | 01-March-2025 to 29-February-2028 | $285,000.00 |
| Immune-checkpoint engineered beta cells as treatment for T1D | UT Southwestern | Andrew Wang | Cures | 01-October-2023 to 30-September-2026 | $746,818.40 |
| Development of Allosteric G6PC1 Partial Inhibitors | Vanderbilt University | Richard O'Brien | Improving Lives | 01-October-2023 to 08-August-2026 | $549,940.00 |
| Investigation of AKS-107 immunotherapeutic in mice and human cells | Vanderbilt University Medical Center (VUMC) | Rachel Bonami | Cures | 01-July-2024 to 30-June-2027 | $800,000.00 |
| Targeting the Autoimmune Germinal Center Axis in Type 1 Diabetes | Vanderbilt University Medical Center (VUMC) | Rachel Bonami | Cures | 01-September-2023 to 31-August-2025 | $600,000.00 |
| Targeting the Opposing Roles of Prostaglandin E2 Receptors, EP3 and EP4, in the Pathogenesis of Type One Diabetes | Vanderbilt University Medical Center (VUMC) | Maureen Gannon | Cures | 01-October-2023 to 31-March-2026 | $200,000.00 |
| Determination of Iatrogenic Hyperinsulinemia’s Contribution to Insulin Resistance and Endothelial Dysfunction in Type 1 Diabetes | Vanderbilt University Medical Center (VUMC) | Justin Gregory | Improving Lives | 01-March-2020 to 30-June-2025 | $747,585.44 |
| Bcl6 and the B/Tfh axis in type 1 diabetes pathogenesis | Vanderbilt University Medical Center (VUMC) | Dudley McNitt | Cures | 01-March-2024 to 28-February-2027 | $265,320.00 |
| Determination of autoreactive B lymphocyte development by ROS in T1D | Vanderbilt University Medical Center (VUMC) | Christopher Wilson | Cures | 01-July-2023 to 30-June-2026 | $234,766.00 |
| Developing Fit-For-Purpose Patient-reported Outcomes (PRO) Measure(s) in Type 1 Diabetes | Vector Psychometric Group | R. J. Wirth | Cures | 01-February-2025 to 31-March-2027 | $797,087.00 |